Articles tagged with Amyloids
Researchers have discovered that amyloid protein build-up is greater on the left side of the brain, where language processing occurs, in individuals with primary progressive aphasia (PPA). This study provides new insights into the disease process and offers hope for early diagnosis and treatment.
Researchers used PET scans to study the progressive stages of Alzheimer's disease in cognitively normal adults, tracking tau protein accumulation in the brain. The findings suggest that tau imaging could become an important tool in developing therapeutic approaches targeting either amyloid or tau, depending on the disease stage.
Researchers have discovered a critical change in amyloid beta protein shape that explains why smaller bundles are more toxic than larger ones. This understanding may lead to developing drugs to treat diseases like Parkinson's and Type-II diabetes.
A recent study found that mental activity may help delay the onset of Alzheimer's symptoms, but it does not affect the underlying disease changes in the brain. For carriers of the APOE4 gene, continued lifetime learning was associated with lower levels of amyloid plaques.
A recent study published in Neurology found that maintaining mental activity can slow the onset of Alzheimer's symptoms in people without a family history of the disease. For those with the APOE4 gene, continued learning and intellectual activity in middle age can lower amyloid plaque levels.
Researchers are developing longer-lived imaging agents to target soluble oligomers, a potentially neurotoxic form of amyloid beta peptide. This approach may lead to more accurate diagnoses and better understanding of the disease process.
A recent study published in Neurology has revealed that protein clumps associated with Alzheimer's disease are found in the brains of people who have had a head injury. These clumps, called amyloid plaques, were found to be present in patients over a decade after the injury.
Researchers use antibiotic resistance to identify chemicals blocking amyloid formation, providing a new approach to combat these intractable diseases. The study identifies a chemical that blocks amyloid deposits forming from sequences associated with type II diabetes.
Researchers discovered that astrocytes are repelled by amyloid plaques, contrary to previous assumptions. This finding suggests that modifying astrocyte function rather than changing position may be a key response to plaque formation.
A recent study published in Neurology found an association between slow walking speed and amyloid plaques in the brain, which are a hallmark of Alzheimer's disease. The researchers discovered that participants with higher levels of amyloid were more likely to have slower walking speeds.
A study published in the journal Brain found that amyloid plaques around blood vessels in the brain can disrupt astrocyte function, leading to reduced cerebral blood flow. This could account for symptoms such as memory lapses, impaired decision-making, and personality changes associated with Alzheimer's disease.
A team of researchers discovered a molecular mechanism responsible for familial amyloidosis and other life-threatening diseases, including Alzheimer's and Parkinson's. They found that specific mutations can alter the protein's structure, leading to abnormal clumping and organ damage.
Scientists have identified a chemical compound that can potentially be used in eye drops to reverse cataracts. The compound, known as compound 29, was shown to stabilize crystallins and prevent them from forming amyloids, which are the hallmark of cataract disease.
A new study suggests that the brain's immune system can be harnessed to clear amyloid plaques, a hallmark of Alzheimer's disease. Microglia, native brain cells, play a key role in this process, and manipulating their activation may accelerate plaque removal.
Researchers at Temple University Health System have identified a regulatory enzyme defect in Down syndrome that also malfunctions in Alzheimer's disease, leading to the formation of toxic amyloid plaques in the brain. This discovery could lead to the development of a targeted therapy to mitigate dementia in Down syndrome.
Researchers have identified GPR3 as a potential therapeutic target for Alzheimer's disease, finding that its absence alleviates cognitive decline and reduces amyloid pathology in multiple models. The study provides preclinical validation for GPR3, setting the stage for future AD drug development.
A recent IRB Barcelona study has questioned the widely accepted premise about the number of molecules and shape of amyloid beta protein's initial aggregates. The research found that Abeta 40 and Abeta 42 form the same aggregation states, contradicting previous findings, which used a technique that may be biased.
A new study found a variant in the IL1RAP gene associated with higher rates of amyloid plaque accumulation and cognitive decline in Alzheimer's patients. The research suggests targeting the IL1RAP immune pathway may be a viable approach for clearing amyloid deposits and fighting disease progression.
Researchers at McGill University have developed a suite of computer programs to speed up the process of drug discovery for diseases like diabetes and Alzheimer's. The Fibrilizer program analyzes billions of possible genetic mutations to find weak spots in toxic protein strands, potentially leading to new treatments.
Researchers designed molecules that suppress protein aggregation, a process damaging cells in Alzheimer's and type 2 diabetes. The findings reveal a novel class of peptide leads that could pave the way for new treatments.
Researchers developed a novel approach using liquid crystals to detect neuro-degenerative diseases by detecting the protein fibers implicated in their development. The system shows extremely high sensitivity and could enable earlier detection at a lower cost.
A new Lund University study found that both amyloid PET imaging and cerebrospinal fluid samples are effective methods for detecting early-stage Alzheimer's disease. The two methods identified approximately 90% of patients with the disease, making them equally viable options.
Scientists at Trinity College Dublin have discovered a fundamental mechanism underlying Alzheimer's disease, which could lead to new forms of therapy. The research, published in Science Advances, highlights the importance of understanding diseases at the molecular level and finding ways to remove toxic amyloid-beta from the brain.
A study published in Frontiers in Behavioral Neuroscience has confirmed the pathogenic role of beta amyloid in dementia, both in Down syndrome and Alzheimer's disease. Researchers found that people with Down syndrome develop abnormal protein at twice the rate, providing insights into how Alzheimer's naturally progresses.
Researchers have identified a key feature of the Alzheimer's disease-causing Amyloid beta molecule using laser light and fat-coated silver nanoparticles. The study suggests that designing a drug molecule to attack this specific shape could lead to a breakthrough in Alzheimer's treatment.
Researchers at Rockefeller University identified a molecular pathway that can dampen amyloid-β production, a hallmark of Alzheimer's disease. By targeting this pathway, it may be possible to develop drugs to reduce amyloid-β and potentially treat or prevent the disease.
Researchers found that people over 80 years old take over 10 hours to clear amyloid beta 42 from the brain, leading to rising levels and increased Alzheimer's disease risk. The study suggests age-related changes in brain clearance may drive the disease.
A new study reveals that a shorter form of the brain protein beta amyloid can bind to copper safely, potentially offering a protective role against Alzheimer's disease. This discovery challenges the long-held copper hypothesis and may lead to new therapies targeting the condition.
A small study suggests that omega-3 fatty acids and antioxidant supplementation may clear amyloid-beta protein and reduce inflammation in neurological tissues of people with mild clinical impairment. Further clinical studies are needed to verify the findings.
Researchers at University of California, San Diego School of Medicine found that early indicators of Alzheimer's disease are not fixed in a specific sequence, complicating diagnosis efforts. The study suggests that different neurobiological pathways lead to the expression of the disease.
Research shows amyloid PET scans improve diagnosis and treatment outcomes for Alzheimer's patients, especially when used after an indeterminate FDG-PET scan. The study found that 17% of patients who received an amyloid scan experienced statistically significant improvements in cognition over a two-year follow-up.
Two studies analyze amyloid prevalence among adults of varying ages and its association with cognitive impairment. The findings indicate that key risk factors for Alzheimer's disease are also risk factors for amyloid positivity in cognitively normal persons.
Two proteins, Contactin-4 and amyloid precursor protein, bind during embryonic development to stabilize brain cells involved in image stabilization. This finding suggests precise neural connections are crucial for accurate sensory perception and behavior.
The study reveals amyloid beta-42 forms three flat structures with a 'salt bridge' that stabilizes its toxic shape. This discovery provides new insights into amyloid propagation in Alzheimer's disease and may impact the effectiveness of existing treatments.
Researchers found that elevated blood sugar can rapidly increase amyloid beta levels in the brain, contributing to Alzheimer's disease. The study suggests a new connection between diabetes and Alzheimer's, providing a potential therapeutic target for treatment.
A novel approach has been identified to block amyloid production in an Alzheimer's mouse model, promising a potential early therapeutic intervention. The study found that the most promising compound, P8, can be administered to individuals at high risk of developing the disease and may have few side effects.
A comprehensive review of research on inhibiting beta amyloid production offers insights into the potential for Alzheimer's treatment. The study examines the role of proteolytic secretases and their viability as therapeutic targets.
A new review of the amyloid-beta peptide, a key component of senile plaques in Alzheimer's disease, has been published in Chemical Reviews. The study combines experimental and theoretical aspects and provides a comprehensive state-of-the-art overview of research on this protein.
A Mayo Clinic study of over 3,600 postmortem brains reveals that tau protein is the primary driver of cognitive decline and memory loss in Alzheimer's disease. Amyloid buildup, while toxic, does not play a major role in disease progression, according to researchers.
Researchers developed a new brain image analysis method to track beta-amyloid plaque deposition in Alzheimer's disease, using positron emission topography (PET). The new approach, which uses cerebral white matter as a reference region, improves the tracking of amyloid changes and evaluates investigational treatments.
A study of over 1,200 cognitively normal individuals aged 30-95 found that men experienced worse memory decline and lower hippocampal volume than women, while APOE ?4 carriers had greater amyloid accumulation from age 70 onwards.
A new study by UCLA researchers has shown the feasibility of a blood-based test for diagnosing Alzheimer's disease, offering a safer and more affordable alternative to current methods. The test uses blood protein panels to predict brain amyloidosis with modest accuracy.
Scientists have discovered that abnormal protein amyloid accumulates inside neurons of people as young as 20, which may contribute to Alzheimer's disease. The study found that this early accumulation leads to the formation of toxic clumps that damage and kill neurons.
Research found that brain amyloid stimulates pancreas fibril growth and vice versa, raising hopes for understanding the connection between AD and T2D. Islet amyloid peptide, derived from pancreatic cells, is also present in human brain senile plaques.
Researchers have identified a molecular chaperone that can break the critical cycle leading to Alzheimer's disease. The molecule, Brichos, inhibits secondary nucleation, preventing the formation of toxic oligomers and amyloid fibrils, which are hallmark of the disease.
Scientists at UC Davis and Rice University have developed methods to manipulate natural proteins into amyloid fibrils with predictable heights. These self-assembling fibers show great toughness, withstanding boiling, digestive proteins, and ultraviolet radiation, making them suitable for tissue engineering and other applications.
Researchers discovered a protein in E. coli that inhibits the accumulation of toxic amyloids, a key feature of Parkinson's disease. The finding could lead to a new therapeutic approach for treating Parkinson's.
Researchers have developed a non-invasive MRI approach that can detect Alzheimer's disease in its earliest stages, identifying toxic amyloid beta brain toxins. The technique has the potential to improve diagnosis and treatment of the disease, which affects one out of nine people over 65.
Research participants who reported greater sleepiness had higher amyloid accumulation in cerebral cortex regions heavily affected in Alzheimer's disease. This suggests that sleep disturbance may be an early target for intervention to prevent cognitive deficits.
Researchers discovered that yeast cells can clear themselves of misfolded prion proteins by activating a stress response and producing specific heat-shock proteins. This finding suggests a new approach to treating diseases associated with prion misfolding, such as Alzheimer's, Huntington's, and Parkinson's.
A new neurological disease closely resembling Alzheimer's disease, called primary age-related tauopathy (PART), has been defined and established criteria for diagnosis. PART is characterized by cognitive impairment without amyloid plaques, but with neurofibrillary tangles composed of a protein called tau.
Researchers at TSRI have discovered a process that can catch unstable proteins before they form toxic clusters, reducing their secretion and aggregation. The approach targets the Unfolded Protein Response pathway and involves activating transcription factor ATF6 to increase protein folding and trafficking.
Investigators from Massachusetts General Hospital developed a novel culture system that reproduces the full course of events underlying Alzheimer's disease. The system confirms the amyloid hypothesis, which suggests that deposition of beta-amyloid plaques in the brain is the first step in a cascade leading to neurodegenerative disease.
Researchers studied adults with Down syndrome to understand the role of amyloid-β protein in memory and cognitive function. Contrary to expectations, many individuals with elevated amyloid-β levels did not exhibit negative consequences, highlighting the complexity of Alzheimer's disease.
Researchers found that bexarotene reduces amyloid-beta levels in late-stage Alzheimer's mice but increases them in early stages. This study suggests a personalized treatment approach for APOE4 carriers, who may benefit from short-term treatment in later disease stages.
Researchers have developed a new method to measure structurally modified proteins in complex biological samples, enabling the analysis of thousands of proteins. The method uses a combination of digestion enzymes and Selected Reaction Monitoring to quantify protein quantities and determine structural changes.
Researchers found that geniposide, a component of the Chinese herbal formula Tongluojiunao, protects hippocampal neurons from Aβ1-mediated cell death via a non-classical estrogen signaling pathway. This study suggests a new potential therapeutic approach for Alzheimer's disease.
The study found that high doses of Notch-1 signaling pathway inhibitor prolonged the survival of PC12 cells after Aβ25-35 induction, decreasing apoptosis-related proteins and increasing antioxidant enzyme activity. The results suggest a protective effect against amyloid beta-peptide-induced cell death.
Researchers at Boston University School of Medicine have discovered that pre-treatment with the anti-aging protein Klotho can prevent neuron death in the presence of toxic amyloid and glutamate. This finding suggests a potential treatment approach for Alzheimer's disease, which affects millions of Americans.
A novel HIF-1α viral vector effectively reduces apoptosis in primary cultured hippocampal neurons exposed to amyloid-beta protein. This breakthrough may lead to the development of gene therapy as a potential clinical treatment for Alzheimer's disease.